Resources

This report contains the Medicare Benefits Schedule (MBS) Review Taskforce's findings and recommendations to the Australian Government on its review of neurology and neurosurgery.

The Indigenous Australians’ Health Programme (IAHP) funds comprehensive primary health care services. This report provides insight into the program’s efficiency and return on investment.

This agreement between the Government and Medicines Australia (MA) facilitates cooperation between them to ensure the future sustainability of the Life Saving Drugs Program.

This document summarises the Medicare Benefits Schedule (MBS) Review Taskforce’s recommendations in response to the Dermatology, Allergy and Immunology Clinical Committee report.

The Accessibility Action Plan sets out how we will work together to build and strengthen our culture. We want to be an employer of choice for people with disability and those who care for people with disability.

The Newborn Bloodspot Screening National Policy Framework guides the national policies needed to support the ongoing success of newborn bloodspot screening in Australia.

This report summarises the result of consultations about wellness and reablement approaches in the aged home care sector, which Nous Group held in 2017.

This framework outlines how information in My Health Record can and cannot be used for research, policy and planning purposes. My Health Record data will be used to provide insights into the effectiveness of services and treatments to help us improve Australia's health system.

This report includes recommendations from the Eating Disorder Working Group, which the Medicare Benefits Schedule (MBS) Review Taskforce revised and endorsed following consultation with stakeholders.

This report includes recommendations from the Oncology Clinical Committee, which the Medicare Benefits Schedule (MBS) Review Taskforce revised and endorsed following consultation with stakeholders.

This document summarises the Medicare Benefits Schedule (MBS) Review Taskforce’s recommendations in response to the Spinal Surgery Clinical Committee report.

This summary of the Medical Technology, Biotechnology and Pharmaceutical (MTP) Sector growth plan includes a profile of the current sector, the growth plan and the future outlook.

BreastScreen Australia services and State Coordination Units (SCUs) use this form to record the Service and/or SCU’s performance against those NAS Measures in which they are responsible for. It must be submitted as part of an application for accreditation.

The Health Portfolio Budget Statements for the 2018 to 2019 financial year outline how the Government has allocated resources to outcomes for all entities within our portfolio.

BreastScreen Australia services and State Coordination Units (SCUs) use this form to appeal against an accreditation decision of the NQMC.

BreastScreen Australia services and State Coordination Units (SCUs) use this form when intending on commencing a new unit within an existing BSA Service commences, or establishing a new BSA Service.

BreastScreen Australia services and State Coordination Units (SCUs) use this form to ask for an extension to their current accreditation period by up to 9 months.

This document summarises the Medicare Benefits Schedule (MBS) Review Taskforce’s recommendations in response to the Endocrinology Clinical Committee report.

This document outlines how governments will address sexually transmissible diseases and blood-borne viruses among Aboriginal and Torres Strait Islander people.

This document summarises the Medicare Benefits Schedule (MBS) Review Taskforce’s recommendations in response to the Renal Medicine Clinical Committee report.

We investigate and enforce the laws relating to tobacco products. This policy outlines the principles we use to guide our decisions and actions in enforcing these laws.

This report outlines the key findings and recommendations of the Expert Health Panel for PFAS. It includes a comprehensive review of recent literature reviews regarding Australian and international evidence on potential human health effects of PFAS exposure.

This reports updates a literature review that looked at international and Australian clinical, academic and policy journals, and media articles or sources in relation to biosimilar medicines, to help inform policy development and communication activities. It covers December 2017 to February 2018.